Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Transfer of gp209-2M Sensitized Lymphocytes in Metastatic Melanoma
NCT00019487Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 1998
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gp209-2M-sensitized autologous lymphocytes in melanoma (4 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Nov 1998; status: completed.
02
Drugs
gp209-2M-sensitized autologous lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00019487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019487.